said Takeda Ventures Senior Partner Rob Woodman.
The notes will be converted in Emendo’s planned B round financing intended to allow the company to advance its high precision gene editing biotherapies into initial clinical trials. Emendo is moving several preclinical programs through optimization, in preparation for moving towards the clinic in a number of promising clinical indications.
Emendo’s gene editing program, OMNI, enables extremely specific gene editing which minimizes off target cuts and allows for highly focused therapeutic intervention in complex genetic diseases.
Emendo’s CEO, David Baram, says:
“We’re pleased to be working with an innovative global pharmaceutical leader such as Takeda. This agreement further positions Emendo as a leading, next-generation, high-precision, gene editing company and promotes its allele specific editing programs that can potentially cure severe genetic disorders.”